Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139122 · ClinicalTrials.gov registry record · Phase 1
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
A Phase 1 study of Dry Eye Disease and Dry Eye Syndrome, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT04139122: Completed Phase 1 study of Dry Eye Disease and Dry Eye Syndrome, sponsored by Senju Pharmaceutical Co..
NCT04139122 is a Phase 1 study of Dry Eye Disease and Dry Eye Syndrome that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 89 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04139122, a Phase 1 study of Dry Eye Disease and Dry Eye Syndrome, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease
Primary Outcome
Number of participants with adverse events by severity are summarize in each cohort. Adverse events are reported as Treatment-Emergent Adverse Events (TEAEs), which are defined as any event not present before exposure to the study drug or any event already presented that worsened in either intensity or frequency after exposure to the study drug.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SJP-0132
Study Locations (1)
California
- Senju Investigational Site - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2019-10-05 |
| Est. Completion | 2020-03-03 |
| Phase | Phase 1 |
What the finished NCT04139122 record still lists
NCT04139122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04139122 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04139122 about?
NCT04139122 is a clinical study titled "Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease". This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease
What is the current status of trial NCT04139122?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2019-10-05. Estimated completion is 2020-03-03.
What conditions does trial NCT04139122 study?
This clinical trial studies the following conditions: Dry Eye Disease, Dry Eye Syndrome.
What interventions are being tested in trial NCT04139122?
The interventions under investigation include: Placebo (DRUG), SJP-0132 (DRUG).
Who is sponsoring clinical trial NCT04139122?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04139122 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04139122's enrollment target sits among peer trials
89 24th of 33 higher than 10 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
COMPLETED · Phase 1
-
Study Evaluating Techniques for Measuring Tear Production
COMPLETED · Phase 1
-
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
COMPLETED · Phase 1
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI